To test the hypothesis that Sydenham chorea (SC) immunoglobulin G (IgG) autoantibodies bind to specific neuronal surface proteins, whereas IgG from patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) or Tourette syndrome (TS) do not bind to neuronal surface proteins.
Sydenham chorea (SC) is the principal neurologic manifestation of acute rheumatic fever, a poststreptococcal autoimmune disorder. SC is characterized by chorea and neuropsychiatric features such as obsessive-compulsive disorder (OCD). Reports of the presence of serum autoantibodies and the therapeutic benefit of plasma exchange suggest that SC may be due to a pathogenic antibody response. [1] [2] [3] [4] Additionally, an outbreak of streptococcal pharyngitis associated with tic disorders led to the hypothesis that some cases of Tourette syndrome (TS) and OCD are precipitated by streptococcus infections. This led to the term pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). 5 Autoantibody detection and the identification of their brain antigens in SC and PANDAS has been the object of scrutiny for some time. 1, [6] [7] [8] [9] Most studies in SC using immunohistochemistry and Western blotting have reported elevated antibody binding. 1, 4, 7 However, in PANDAS and TS, there have been inconsistent results with positive 4,10,11 and negative findings. 9, 12 It is increasingly recognized that pathogenic autoantibodies typically bind to cell surface neuronal antigens that are involved in cell function. [13] [14] [15] Therefore, to define pathogenic antie-Pub ahead of print on March 16, 2011, at Supplemental data at www.neurology.org bodies, it is necessary to use live cells expressing antigens in their native conformational state. We used a live neuronal cell line and FACS to compare cell surface IgG binding between children with SC, PANDAS, TS, and controls. We showed that cell surface IgG binding is present in patients with SC, but not in PANDAS or TS.
METHODS Patients and controls. The following patients and controls were recruited between 2000 and 2009. SC (n ‫؍‬ 11). All patients fulfilled criteria for SC and had positive streptococcal serology (table) . Serum samples were taken acutely during active chorea, and before the use of any immune therapy.
PANDAS (n ‫؍‬ 12). Between 2000 and 2009, over 300 patients with TS were seen by R.C.D. Among these patients, 12 patients who best fulfilled the criteria for PANDAS were recruited for this study. 5 Serum samples were taken during acute exacerbations of their tic disorders which were associated with a clinical pharyngeal infection plus evidence of streptococcal infection. 5 The onset of disease, clinical course, and clinical characteristics are described in the table. The main differentiating feature of PANDAS was the abrupt and dramatic onset of symptoms associated with streptococcal infection (present in 10 of 12 patients) or the relapsing-remitting course associated with streptococcal infections (present in 7 of 12 patients) (table). Although all 12 patients with PANDAS had one or more clinical exacerbations associated with streptococcal infections, only 7 had multiple exacerbations and a relapsing-remitting course as previously described. 5 All patients with PANDAS had elevated acute antistreptolysin-O (ASO) titers Ͼ240 IU/mL (mean 960, range 400 -2,200). 16 All convalescent ASO titers were reduced during remission. The 7 patients with a relapsing-remitting course had further elevation of ASO titer associated with clinical relapse. TS (n ‫؍‬ 11). All patients with TS fulfilled DSM-IV criteria. All had active tic disorders at the time of serum sampling, but none had the PANDAS phenotype. The 11 patients were otherwise selected randomly from approximately 300 patients seen in the tic clinic by R.C.D. during this time period.
Healthy children (HC, n ‫؍‬ 11, 6 male, mean age 11 years, range 9 -13 years). These children were healthy with no infectious or neurologic disorders.
Other neurologic diseases (OND, n ‫؍‬ 11, 6 male, mean age 6.0 years, range 2-15 years). These children had noninflammatory neurologic disorders including epilepsy and developmental syndromes.
All serum samples had IgG concentration measured by nephelometry (BN ProSpec, Siemens), and IgG values were within the normal range (6.2-14.4 g/L). The IgG mean and range did not significantly differ between any patient and control groups.
Standard protocol approvals, registrations, and patient consents. Ethics approval for this study was granted by the
Children's Hospital at Westmead ethics committees (HREC 2007/035 and SSA 07/CHW/58), and written informed consent from all patients was obtained.
Cell-based assay for detection of IgG binding to cell surface neuronal antigens. FACS was recently used to dem-
onstrate IgG binding to cell surface antigens in CNS immunemediated diseases. 13, 17 We used FACS analysis to detect antibody binding of patient serum IgG to the surface of differentiated human SH-SY5Y cells and to HEK293 as a non-neuronal control cell line. SH-SY5Y cells were differentiated with 10 M retinoic acid (RA) for 3 days (Sigma-Aldrich), or 10 M RA for 3 days followed by 80 nM phorbol-12-myristate 13-acetate (PMA) (Sigma-Aldrich) for 3 days. 18 The cells were then harvested using versene (Invitrogen), washed in PBS supplemented with 2% FBS (PBS/FBS), and then resuspended at a density of 100,000 cells/mL. A total of 50,000 of SH-SY5Y/RA and HEK293 cells were incubated with serum at a 1:100 dilution in V-bottom plate (Corning) for 1 hour at RT. Cells were then was added to the cells to exclude dead cells. In addition, differentiated SH-SY5Y cells were also fixed and permeabilized with 1% PFA and 0.1% TritonX for 10 minutes at RT to analyze the binding of patient sera to intracellular antigens. In this case, cells were washed in PBS/FBS with 0.02% saponin. A total of 10,000 events/well were recorded on a BS LSRII instrument equipped with a high-throughput sampler (BD Biosciences). Data analysis was performed using Flow Jo software and Excel (Microsoft). Binding was expressed as mean fluorescence intensity (MFI). An MFI greater than mean ϩ 3 SD of the control samples was considered positive. Each experiment was performed 3 times.
Statistical analysis. The Mann-Whitney U test was used to
compare antibody titer between patients and controls.
RESULTS SH-SY5Y cells were differentiated by treatment with RA into neuron-like cells as shown by upregulation of neuronal marker tyrosine hydroxylase (TH) and outgrowth of neurites ( figure 1, A When we fixed and permeabilized RAdifferentiated cells, there was no difference in results obtained; the only group to show any significant binding was the SC group with 6/11 sera above threshold (mean SC MFI 105.9 Ϯ 70.2, p Ͻ 0.05, figure 2B ). Interestingly, the 6 patients above the threshold (healthy control mean ϩ 3 SD, MFI 78.3) were identical in experiments on live (figure 2A) and fixed and permeabilized cells ( figure 2B ). There was no correlation of total serum IgG levels with neuronal binding in any experiment.
We performed the same experiments using nonneuronal HEK293 cells. No serum from any groups showed positive binding above threshold, or elevated mean MFI ( figure 2C ), suggesting that the IgG surface binding in SC samples was directed to a neuronal-specific cell surface antigen.
DISCUSSION
Our study used a quantitative method to demonstrate elevated IgG cell surface binding in SC. Previous studies have shown IgG binding to live neurons using immunohistochemistry, and have defined lysoganglioside as an important and potentially pathogenic antigen assuming a mo- lecular mimicry hypothesis. [3] [4] [5] Our article strengthens the hypothesis that patients with SC have IgG binding to neuronal specific cell surface antigens. We found that differentiation of the SY-SH5Y cells asso-ciated with increased dopaminergic characteristics increased the IgG cell surface binding. In addition, permeabilizing the cells and revealing intracellular antigens did not alter the results. Indeed, the same samples were positive for IgG binding, suggesting that the important antigen in SC is expressed on the cell surface. In this study, we have not proposed which antigen is involved in IgG cell surface binding. Previously proposed antigens in SC include lysoganglioside, tubulin, and glycoytic enzymes, 6, 8, 19 although it is possible that the dominant pathogenic antibody is yet to be defined. We aimed to determine whether patients with PANDAS or TS had similar cell surface IgG binding. The patients with PANDAS were recruited from a clinical service for children with TS. The patients in the PANDAS group were selected as they all had one or more exacerbations associated with streptococcal infections, although only 7 had multiple relapses associated with streptococcal infections and a relapsing-remitting course. 5 All serum samples were taken during postinfectious clinical deteriorations associated with positive streptococcal serology. There was no evidence of elevated cell surface IgG binding in any patient with PANDAS or TS. These findings suggest that the antibody repertoire in PANDAS and TS is different from that of SC.
It is possible that the sensitivity of our assay is too low to demonstrate IgG cell surface binding in PANDAS or TS. It is also likely that the differentiated SH-SY5Y cells do not express all potential surface and intracellular epitopes found in the brain. Our findings contradict previous reports that have shown elevated lysoganglioside IgG binding in PANDAS and SC compared to controls. 4 Alternatively, it is possible that different immune processes other than autoantibody production are important in the clinical fluctuations of PANDAS and TS, as recently described. 20, 21 Using a quantitative method we have strengthened the hypothesis that SC is mediated by an autoantibody that binds to neuronal cell surface antigens. By contrast, we have failed to demonstrate a similar finding in PANDAS and TS, therefore weakening the autoantibody hypothesis in these conditions.
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